|
Bacitracin is a mixture of related cyclic peptides produced by organisms of the licheniformis group of ''Bacillus subtilis'' ''var'' Tracy, first isolated in 1945. These peptides disrupt both gram positive and gram negative bacteria by interfering with cell wall and peptidoglycan synthesis. Bacitracin is primarily used as a topical preparation (as it is can cause kidney damage when used internally). The widespread use of bacitracin, even for minor wounds where it is not useful, contributes to antibiotic resistance. == History == The drug's unique name derives from the fact that it was isolated by John T. Goorley from a girl named Margaret Treacy (1936–1994):〔https://files.nyu.edu/jmm257/public/other/bacitracin.html〕 The surname was misspelled and the name was shortened to the more common spelling Tracy ''One strain isolated from tissue debrided from a compound fracture of the tibia was particularly active. We named this growth-antagonistic strain for the patient, "Tracy I." When cell-free filtrates of broth cultures of this bacillus proved to possess strong antibiotic activity and to be non-toxic, further study seemed warranted. We have called this active principle "Bacitracin.''"〔Johnson B, Anker H, Meleney F (1945). "Bacitracin: a new antibiotic produced by a member of the B. subtilis group".''Science'' 102 (2650): 376–377.〕 It was approved by FDA in 1948. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Bacitracin」の詳細全文を読む スポンサード リンク
|